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INTRODUCTION
The head-shaking test (HST) is a simple technique that clinicians can easily perform to identify dynamic asymmetry in the vestibu-
lo-ocular reflex. Patients with a unilateral vestibular lesion show, after the resolution of spontaneous nystagmus, a new transient 
nystagmus. In these patients, the transient nystagmus is induced by rapid head shaking (10-20 cycles) performed in the yaw plane 
[1-3]; this nystagmus is referred to as head-shaking nystagmus (HSNy). The regulation of HSNy follows an analytic model that involves 
a central velocity-storage mechanism for sustaining the vestibular inputs, the principle of Ewald’s second law, and the adaptation of 
primary vestibular afferent activity [1, 4]. A prolonged, lower-amplitude reversal phase can be also detected after the initial response 
following the horizontal head shaking (biphasic) [1, 4]. An HSNy that beats toward the healthy ear observed in patients affected 
with unilateral peripheral lesions is a common deficiency-type nystagmus; instead, an HSNy that beats toward the affected ear in 
patients with unilateral peripheral lesions may be identified as a recovery or irritative-type nystagmus [5]. This test can be used in 
patients who suffer from Meniere’s disease (MD); in this case, the HSNy can be both of deficiency or irritative-type depending on the 
stage of the disease [6]. Furthermore, a “perverted” HSNy (a nystagmus in a plane other than that being stimulated) in MD has been 
observed; in this case, the nystagmus presents a vertical component [7, 8].
MD is a disease that affects the inner ear characterized by an endolymphatic hydrops [9-11]. The hydrops, triggered by environmental 
factors, such as virus or vasoconstriction, that in genetic predisposed subjects can determine an increased immunity response to 
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these factors [12-14], is generally temporary (between 20 min and few 
hours) and determines a series of audiovestibular symptoms, such as 
vertigo, tinnitus, fullness, and hearing loss [9, 10, 15]. Recently, research-
ers have identified a correlation between the presence of migraine 
and MD [16]; probably, in these cases, the effect of vasoconstriction 
(very common in migraine episodes) may be the cause of the MD 
crisis. The MD crisis can have a spontaneous resolution especially in 
the first year of affection, but in most cases requires pharmacological 
treatment [9, 10]. Anyway, the best method to limit the severity of the 
crisis is its prevention [9, 10].
Although performing vestibular clinical examination in patients af-
fected with MD may lead to variable observational findings [17-20], ab-
normal results are easily observable using vestibular tests that gen-
erate objective findings for the identification of HSNy, followed by 
the vibration-induced nystagmus (VIN) and the caloric test [19]. Some 
authors observed that an irritative-type HSNy may be indicative of 
the recurrence of a crisis within a very short time [21]. Furthermore, 
the presence of an HSNy directed to the affected ear observed during 
the MD recovery period might indicate the oncoming recurrence of a 
vertigo attack within a few days [8, 22].
We hypothesize that in the first stages of MD, there is a complete ves-
tibular functional recovery after the attack due to the transition of the 
hydrops. Furthermore, patients in the early stage of MD do not have 
permanent damage of the vestibular receptors, typical of the more 
advanced stages. Taken together, in the early stage of MD, we expect 
to observe a purely dysfunctional HSNy. Based on these hypothesis 
and previous findings, the aim of the present study was to evaluate 
the prognostic value of HSNy for the prediction of an imminent ver-
tigo attack in patients affected by MD by performing a qualitative 
evaluation of HSNy immediately after the resolution of an attack in a 
sample of patients recently diagnosed with early-stage MD.
MATERIALS AND METHODS
Study design
This was a longitudinal, unicenter prospective study conducted in 
the vestibular center of our university hospital between February 
2015 and September 2018. The study was approved by the institu-
tional review board commission of the university hospital without 
releasing an identification number, following national law, in accor-
dance with the Declaration of Helsinki. All subjects signed a written 
consent before being included in the study.
Patient enrollment
All patients aged between 18 and 65 years lamenting an episode of 
vertigo that occurred within 24 h of consultation were consecutive-
ly evaluated. All patients underwent clinical history collection, clin-
ical observation for spontaneous and positional nystagmus, otomi-
croscopy, and pure tone audiometry (PTA). The following vestibular 
tests were performed: HST, head impulse test (HIT), VIN at 100 Hz, 
subjective visual vertical (SVV), cervical vestibular-evoked muscular 
potentials (c-VEMPs), and caloric test. The patients were observed at 
three time points: within 24 h of vertigo onset (T0), after 48 h (T1), 
and after 14 days (T2). Specifically, at T0, the patients underwent PTA, 
HST, VIN, SVV, and c-VEMPs but not to caloric test and HIT. At T1, the 
patients were investigated with all vestibular tests. At T2, the patients 
repeated PTA evaluation. All patients were invited to complete a clini-
cal daily diary detailing the recurrence of new vertigo spells. Pharma-
cological treatment with 48 mg of beta-histidine (24 mg two times 
daily) was initiated at T0 in all patients.
Inclusion criteria was a diagnosis of unilateral definitive early-stage 
MD (<6 months) according to the Barany Society criteria [23] with a 
maximum of three vertigo episodes during the last 6 months. In de-
tails, diagnosis was based on clinical history and audiovestibular ex-
amination; patients with (1) two or more episodic vertigo syndromes 
limited to a period of 20 min to 12 h, associated with (2) low- to medi-
um-frequency sensorineural hearing loss (SNHL) identified in at least 
one observation, and (3) fluctuating aural symptoms (hearing, tinni-
tus, and/or fullness) in one ear were classified as unilateral definitive 
MD and were included in the study.
Exclusion criteria were as follows: patients who did not fully meet the 
diagnostic criteria for MD, had a clinical diagnosis of bilateral MD, a 
history of MD of >6 months, middle ear pathology, or other forms of 
vertigo due to neurological disorders, affected by migraine or other 
known vestibular disorders, or with familial history of MD. Addition-
ally, patients classified as definitive MD with persistent spontaneous 
nystagmus were excluded because the presence of a spontaneous 
nystagmus is indicative of static vestibular asymmetry. Patients who 
presented with a new vertigo episode between the first (T0) and the 
second (T1) observation were also excluded from the study.
Pure tone audiometry
All patients underwent PTA at T0 and T2. PTA was measured at fre-
quencies of 250, 500, 1000, 2000, 3000, 4000, and 8000 Hz; data at 
frequencies of 500, 1000, 2000, 3000, and 4000 Hz were used in the 
study. 
Head-shaking test
HST was performed at T0 and T1. The patient was seated, and the 
physician flexed his/her head (nose directed down) by 30°; the 
head was passively rotated horizontally by ±45° at 1 Hz for 20 s, 
followed by electro-oculo-graph recording looking for an evoked 
nystagmus. Transient nystagmus was observed after rapidly shak-
ing the head when a vestibular imbalance occurred. HSNy was 
considered pathologic when, by shaking the head, it appeared for 
at least two clear post-rotation horizontal nystagmic beats with a 
peak slow phase eye velocity over 5°/s [8, 24]. HSNy was classified as 
monophasic (single phase) or biphasic (two phases) and then, as 
a function of the ear affected with the disease, was defined as ip-
silesional (nystagmus directed to the same side as the affected ear) 
or contralesional (nystagmus directed to the healthy ear). In case 
of a biphasic HSNy, the first component (first phase of nystagmus) 
defined if this was ipsilesional or contralesional [1-4, 8]. To achieve the 
aim of the present study, only the horizontal component of the nys-
tagmus and not the concomitant vertical or torsional components 
was evaluated.
Statistical Analysis
The odds ratios (ORs) in patients with ipsilesional HSNy and the sensi-
tivity and the specificity of the HSNy toward the prediction of a new, 
imminent vertigo attack were calculated using Stata® (www.stata.
com). A p-value <0.05 was considered statistically significant. 
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RESULTS
Initial visit (T0—within 24 h after vertigo attack)
A total of 20 (11 female and 9 male) subjects were included in the 
study. The average age of the patients was 49.4 years (standard de-
viation 10.4, 95% confidence interval (CI): 36-62). All patients had 
unilateral SNHL on the same side of the MD. The PTA evidenced an 
auditory threshold indicative of low or mild SNHL especially for low 
frequencies. The average PTA was 45.6 dB at 500 Hz, 46.1 dB at 1000 
Hz, 25.6 dB at 2000 Hz, 30 dB at 3000 Hz, and 34.4 dB at 4000 Hz 
(Figure 1).
The HST performed within 24 h of vertigo onset showed that 16 
(80%, 8 male and 8 female) patients presented with an ipsilesional 
HSNy, whereas 4 (20%) subjects did not present with HSNy. In pa-
tients with ipsilesional HSNy, 4 (25%) subjects were affected with a 
biphasic HSNy, and the remaining 12 (75%) subjects were affected 
with a monophasic form.
Second visit (T1—48 h after vertigo attack)
At T1, the patients underwent HST and a complete vestibular test 
battery. Nineteen (95%) patients observed at T0 were re-tested at 
T1. One subject, who presented an ipsilesional HSNy at T0, suffered 
from a vertigo episode between the first and the second follow-up 
and was excluded from the second HST according to our inclusion/
exclusion criteria. 
Eight (42.1%, 4 male and 4 female) patients presented with an HSNy 
after the HST. Six (75%) patients presented with an ipsilesional HSNy, 
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Table 1. Summary of data related to patients recruited in the study: Type of head-shaking nystagmus at head-shaking test performed at T0 (within 24 hours 
from the vertigo spell) and T1 (within 48 hours) and daily trend of new crisis during the follow up (14 days)
           Follow-up (14 days)       Crisis
Patients Sex Age 1° HST (T0) 2° HST (T1) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 T2
1 F 41 Ipsi (monoph) Ipsi (monoph)   X            Yes
2 M 55 Ipsi (biphasic) Absent               Not
3 F 36 Ipsi (biphasic) Contra (monoph)               Not
4 F 40 Absent Absent               Not
5 F 64 Ipsi (monoph) Ipsi (monoph)    X           Yes
6 M 60 Ipsi (monoph) Absent              X Yes
7 M 48 Ipsi (monoph) Absent               Not
8 F 43 Absent Absent               Not
9 M 41 Ipsi (monoph) Ipsi (monoph)  X             Yes
10 M 57 Ipsi (monoph) Ipsi (monoph)     X          Yes
11 F 60 Absent Absent               Not
12 M 52 Ipsi (biphasic) Absent               Not
13 F 62 Ipsi (monoph) Contra (monoph)               Not
14 F 43 Ipsi (monoph) Absent               Not
15 M 28 Ipsi (monoph) Ipsi (monoph) X              Yes
16 M 55 Absent Absent               Not
17 F 52 Ipsi (biphasic) Absent               Not
18 M 63 Ipsi (monoph) Ipsi (monoph)       X        Yes
19 F 39 Ipsi (monoph) Absent                             Not
Ipsi: ipsilesional head-shaking nystagmus; Contra: contralesional head-shaking nystagmus; Monoph: monophasic head-shaking nystagmus; Biph: biphasic head-shaking nystagmus.
X indicates the day of the onset of the first new crisis during follow-up.
Figure 1. Pure tone audiometry thresholds for patients included in the study at 
T0 and T2. 
and 2 (25%) patients showed a contralesional HSNy. For the eight pa-
tients who presented with an HSNy, the VIN was the only test out of 
the normal range results and, therefore, indicative of a vestibular im-
balance. Specifically, we observed a case in which both the VIN and 
the HSNy were ipsilateral. The VIN was directed to the healthy side 
in three cases; the results of the HST showed an ipsilesional HSNy in 
two subjects and a contralesional one in one case. None of the 11 pa-
tients in whom the HSNy was not evocable after the HST presented 
altered results in the other vestibular tests.
Third visit (T2—14 days after vertigo attack)
At T2, the patients performed a new PTA to evaluate hearing recov-
ery, and the evaluation of the clinical diary of vertigo spells occurred 
between T1 and T2.
The average PTA was 17.8 dB at 500 Hz, 21.7 dB at 1000 Hz, 21.1 dB 
at 2000 Hz, 28.3 dB at 3000 Hz, and 34.4 dB at 4000 Hz with a sig-
nificant improvement for low frequencies, whereas no changes were 
observed for mid and high frequencies.
Seven (36.8%) out of the 19 patients re-evaluated at T1 presented 
with a new vertigo episode during the observational period. All of 
these subjects had an ipsilesional HSNy at T0 that persisted at T1 
in 6 (85.7%) cases. In one case, we observed a recurrence of verti-
go in a subject in whom the HSNy was absent at T1. Details on the 
timing of the onset of a new crisis are presented in Table 1. On the 
contrary, we did not observe a new crisis in any of the eight patients 
with an absence of HSNy at T1, even in patients with an HSNy at T0. 
This sample of patients also included subjects who presented with a 
biphasic HSNy. Patients with an ipsilesional HSNy after 48 h had an 
OR of 108.3333 (95% CI: 3.8465-3051.1313) with a statistically signif-
icant increased risk (p<0.005) of developing a new crisis within 15 
days. The sensitivity of ipsilesional HSNy toward predicting the short-
term recurrence of a new attack was 100% and 85.7% at T0 and T1, 
respectively, and the specificity was 46.6% and 100% at T0 and T1, 
respectively. 
DISCUSSION
The results of our study show that patients with MD present with 
an increased rate of ipsilesional HSNy in the early stages of the dis-
ease, as also shown by other authors [24, 25]. Furthermore, when this 
is evoked 48 h after a recent vertigo spell, these patients have an in-
creased risk of developing a new MD attack within 15 days. 
In 1995, Kamei [5] investigated the predictive value of HSNy in patients 
affected with MD as an early indicator of a new crisis. He analyzed a 
sample of eight patients with MD and observed that the presence of 
an ipsilesional HSNy during the intercritical phase (recovery period 
between two MD crises) correlated with the onset of a new crisis be-
tween 6 h and 8 days (mean=3.2 days) [24]. Our results are consistent 
with those reported by Kamei; however, we also observed additional 
findings. First, we noted the absence of a contralesional-type HSNy 
in the immediate post-crisis period, and that only the ipsilesional 
HSNy was evoked; this finding is representative of a functional state 
related in time to the crisis and the length of the affliction (duration 
of illness). This result may be correlated to the state of the illness in 
the patients included in our study; in fact, if they were diagnosed as 
definitive MD during the first clinical evaluation (T0), the vestibular 
organ likely had limited damage, and the patients may recover their 
vestibular function quite well after the crisis. This idea was confirmed 
by the results of the HIT, SVV, caloric, and c-VEMP tests and partial-
ly confirmed by the VIN findings that showed a selective, high-fre-
quency imbalance in a minority of cases. Second, we observed, as 
a frequent finding in our sample, the presence of transient reversed 
nystagmus (biphasic) in the phases immediately after the vestibular 
crises. We speculate that this nystagmus may be the expression of a 
Figure 2. Proposal of an algorithm for identifying a patient at risk of a new vertigo attack using the head-shaking test.
428
J Int Adv Otol 2019; 15(3): 425-30
variable vestibular functional state and reflective of the quick activa-
tion of adaptive vestibular mechanisms. 
The most relevant result of our study is the determination of the in-
creased risk of developing a new crisis in a very short period (<14 days), 
as observed in patients with MD, when an ipsilesional HSNy is evoked 
within 48 h from the crisis. Furthermore, this finding was highly sensi-
ble and specific at both the initial visit (100% and 46.6%) and 48 h later 
(85.7% and 100%). In particular, 48 h after the crisis, the sensibility was 
associated with high specificity (100%) by confirming the validity of 
the HSNy at this time point. In fact, we observed six patients with this 
positive finding that presented with a new short-term crisis within 2-10 
days. This finding likely represents a real persistent irritative HSNy. 
In eight patients, we observed an ipsilesional HSNy at T0 only, and we 
considered this to be a recovery HSNy; unfortunately, at this obser-
vational point, this finding was associated with lower specificity than 
the one observed at T1 (46.6% and 100%, respectively). 
Finally, we identified a normal HST (i.e., without an HSNy) in one 
patient who presented with a recurrence of a vertiginous crisis at 
T2. In this patient, the interval time between T1 and the new crisis 
was extremely long (14 days) compared with the recurrence times 
observed in patients who presented with an abnormal response at 
HST (ipsilesional HSNy) (<8 days); therefore, we did not consider the 
recurrence of vertigo in this single case to be a “very imminent event.” 
In addition, the majority of patients in our sample presented with a 
new vestibular crisis within 5 days from T1, and in these cases, the 
HSNy was very sensible (87.5%) and extremely specific (100%). We 
recorded an ipsilesional HSNy at T0 in the seven cases who then de-
veloped new crises; six of the seven patients with an initial ipsilesion-
al HSNy presented with the same finding at T1. The persistence of 
this observation can suggest a group of patients strongly at risk of an 
imminent relapse of vertigo. 
Additionally, we identified the presence of a biphasic HSNy at T0 in 
four patients, and this appears to be a favorable predictive element. 
Furthermore, even if the contralesional HSNy does not appear to be a 
functional state characteristic of the early stages of MD immediately 
after the crisis, we observed this finding in two cases 48 h after the 
crisis. We hypothesize that this may be the expression of a later adap-
tive process similar to the biphasic HSNy evoked after the first HST or 
may represent the initial subclinical, persistent damage to the vestib-
ular receptors. In these cases, evoking a contralesional HSNy at this 
stage does not appear to predict a new crisis in the following days.
To reinforce the predictive value of HSNy, it is relevant to underline 
that none of the four patients with normal HST at the initial visit and 
48 h later (without HSNy) presented with a new vertiginous crisis 
within 14 days. For these cases (absence of positive findings in HST), 
we suggest that a short-term control with HST is not necessary. On 
the contrary, when an ipsilesional HSNy is identified and in the ab-
sence of spontaneous nystagmus, we recommend the repetition of 
HST within 48 h of the crisis (Figure 2). 
In 1999, Kamei [24] reported that the immediate administration of an 
osmotic diuretic when an ipsilesional HSNy is observed successfully 
suppresses the recurrence of vertigo in three out of eight patients [24, 25]. 
While we did not verify this in our study, a targeted therapeutic ap-
proach may be designated in high-risk patients following our sug-
gested algorithm. 
Even though additional studies with larger sample sizes are neces-
sary to confirm our preliminary results, our results are promising and 
clinically relevant because they suggest that the correct follow-up in 
the days immediately following the crisis can potentially optimize 
the therapeutic approach. 
Our study has some limitations. These limitations include the small 
sample size, the absence of a healthy control group, and the absence 
of distortion product otoacustic emission and auditory brainstem re-
sponse evaluation in enrolled patients.
CONCLUSION
We observed that the presence and persistence of an ipsilesion-
al HSNy at different time points in patients with unilateral MD may 
be predictive of a new imminent crisis within 7 days of the second 
follow-up visit. These patients also present an increased risk for a 
short recurrence of a new vertigo attack. Owing to the simplicity of 
the execution of the HST and the high predictive value that we ob-
served in our patients, we recommend its use following our clinical 
algorithm to monitor the possibility of a new crisis and to start in 
high-risk patients an early pharmacological treatment to reduce the 
number of new vertigo attacks. Additional studies are necessary to 
evaluate HSNy in the more advanced stages of the disease and to 
determine if its predictive value in identifying a new imminent crisis 
may be similar to that observed in patients with an early confirmed 
diagnosis of MD. 
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